211 related articles for article (PubMed ID: 31344060)
1. Lectin nanoparticle assays for detecting breast cancer-associated glycovariants of cancer antigen 15-3 (CA15-3) in human plasma.
Terävä J; Tiainen L; Lamminmäki U; Kellokumpu-Lehtinen PL; Pettersson K; Gidwani K
PLoS One; 2019; 14(7):e0219480. PubMed ID: 31344060
[TBL] [Abstract][Full Text] [Related]
2. The Clinical Significance of sICAM-1 in Differentiating Benign Breast Lesions from Breast Cancer.
Chen C; Chen Q; Dong Y; Liu X
Ann Clin Lab Sci; 2020 Sep; 50(5):650-656. PubMed ID: 33067211
[TBL] [Abstract][Full Text] [Related]
3. A Nanoparticle-Lectin Immunoassay Improves Discrimination of Serum CA125 from Malignant and Benign Sources.
Gidwani K; Huhtinen K; Kekki H; van Vliet S; Hynninen J; Koivuviita N; Perheentupa A; Poutanen M; Auranen A; Grenman S; Lamminmäki U; Carpen O; van Kooyk Y; Pettersson K
Clin Chem; 2016 Oct; 62(10):1390-400. PubMed ID: 27540033
[TBL] [Abstract][Full Text] [Related]
4. Nanoparticle-aided glycovariant assays to bridge biomarker performance and ctDNA results.
Gidwani K; Kekki H; Terävä J; Soukka T; Sundfeldt K; Pettersson K
Mol Aspects Med; 2020 Apr; 72():100831. PubMed ID: 31787337
[TBL] [Abstract][Full Text] [Related]
5. Plasma mammaglobin messenger RNA in breast cancer patients as an addition to serum tumor.
El-Attar NI; Gaefar HA
Egypt J Immunol; 2007; 14(2):111-21. PubMed ID: 20306663
[TBL] [Abstract][Full Text] [Related]
6. Identification of a panel of complex autoantigens (LGALS3, PHB2, MUC1, and GK2) in combination with CA15-3 for the diagnosis of early-stage breast cancer.
Zuo X; Chen L; Liu L; Zhang Z; Zhang X; Yu Q; Feng L; Zhao X; Qin T
Tumour Biol; 2016 Jan; 37(1):1309-17. PubMed ID: 26289852
[TBL] [Abstract][Full Text] [Related]
7. Thioredoxin 1 as a serum marker for breast cancer and its use in combination with CEA or CA15-3 for improving the sensitivity of breast cancer diagnoses.
Park BJ; Cha MK; Kim IH
BMC Res Notes; 2014 Jan; 7():7. PubMed ID: 24393391
[TBL] [Abstract][Full Text] [Related]
8. The prognostic significance of LIAISON(R) CA15-3 assay in primary breast cancer.
Nisman B; Maimon O; Allweis T; Kadouri L; Maly B; Hamburger T; Peretz T
Anticancer Res; 2013 Jan; 33(1):293-9. PubMed ID: 23267160
[TBL] [Abstract][Full Text] [Related]
9. CA15-3 is a useful serum tumor marker for diagnostic integration of hybrid positron emission tomography with integrated computed tomography during follow-up of breast cancer patients.
Incoronato M; Mirabelli P; Catalano O; Aiello M; Parente C; Soricelli A; Nicolai E
BMC Cancer; 2014 May; 14():356. PubMed ID: 24886519
[TBL] [Abstract][Full Text] [Related]
10. Alternative antibody for the detection of CA15-3 antigen: a European multicenter study for the evaluation of the analytical and clinical performance of the Access BR Monitor assay on the UniCel Dxl 800 Immunoassay System.
Molina R; Gion M; Gressner A; Troalen F; Auge JM; Holdenrieder S; Zancan M; Wycislo M; Stieber P
Clin Chem Lab Med; 2008; 46(5):612-22. PubMed ID: 18598203
[TBL] [Abstract][Full Text] [Related]
11. Comparison of a novel assay for breast cancer mucin to CA15-3 and carcinoembryonic antigen.
Daly L; Ferguson J; Cram GP; Hars V; George SL; McCarty KS; Bast RC
J Clin Oncol; 1992 Jul; 10(7):1057-65. PubMed ID: 1607912
[TBL] [Abstract][Full Text] [Related]
12. Comparison of serum CA15-3 and CEA in breast cancer.
Hou MF; Huang TJ; Hsieh JS; Huang YS; Huang CJ; Chan HM; Wang JY; Chen YL; Jong SB; Yang CC
Gaoxiong Yi Xue Ke Xue Za Zhi; 1995 Dec; 11(12):660-6. PubMed ID: 8551526
[TBL] [Abstract][Full Text] [Related]
13. Independent prognostic impact of preoperative serum carcinoembryonic antigen and cancer antigen 15-3 levels for early breast cancer subtypes.
Imamura M; Morimoto T; Nomura T; Michishita S; Nishimukai A; Higuchi T; Fujimoto Y; Miyagawa Y; Kira A; Murase K; Araki K; Takatsuka Y; Oh K; Masai Y; Akazawa K; Miyoshi Y
World J Surg Oncol; 2018 Feb; 16(1):26. PubMed ID: 29433529
[TBL] [Abstract][Full Text] [Related]
14. Intensive post-operative follow-up of breast cancer patients with tumour markers: CEA, TPA or CA15.3 vs MCA and MCA-CA15.3 vs CEA-TPA-CA15.3 panel in the early detection of distant metastases.
Nicolini A; Tartarelli G; Carpi A; Metelli MR; Ferrari P; Anselmi L; Conte M; Berti P; Miccoli P
BMC Cancer; 2006 Nov; 6():269. PubMed ID: 17116247
[TBL] [Abstract][Full Text] [Related]
15. [Elevation of serum Ca 15-3 antigen: an early indicator of distant metastasis from breast cancer. Retrospective analysis of 733 cases].
Wojtacki J; Kruszewski WJ; Sliwińska M; Kruszewska E; Hajdukiewicz W; Sliwiński W; Rolka-Stempniewicz G; Góralczyk M; Leśniewski-Kmak K
Przegl Lek; 2001; 58(6):498-503. PubMed ID: 11816740
[TBL] [Abstract][Full Text] [Related]
16. FTO, PIK3CB serve as potential markers to complement CEA and CA15-3 for the diagnosis of breast cancer.
Mi J; Zhang H; Cao W; Yuan C
Medicine (Baltimore); 2023 Oct; 102(42):e35361. PubMed ID: 37861518
[TBL] [Abstract][Full Text] [Related]
17. A novel serum metabolome score for breast cancer diagnosis.
Rashed R; Darwish H; Omran M; Belal A; Zahran F
Br J Biomed Sci; 2020 Oct; 77(4):196-201. PubMed ID: 32546046
[TBL] [Abstract][Full Text] [Related]
18. Correlation between cancer antigen 15.3 value and qualitative and semiquantitative parameters of positron emission tomography/computed tomography in breast cancer patients.
Cervino AR; Saibene T; Michieletto S; Ghiotto C; Bozza F; Saladini G; Evangelista L
Curr Radiopharm; 2014; 7(1):20-8. PubMed ID: 24836946
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of serum CA27.29, CA15-3 and CEA in patients with breast cancer.
Hou MF; Chen YL; Tseng TF; Lin CM; Chen MS; Huang CJ; Huang YS; Hsieh JS; Huang TJ; Jong SB; Huang YF
Kaohsiung J Med Sci; 1999 Sep; 15(9):520-8. PubMed ID: 10561976
[TBL] [Abstract][Full Text] [Related]
20. Diagnostic potential of nanoparticle aided assays for MUC16 and MUC1 glycovariants in ovarian cancer.
Jain S; Nadeem N; Ulfenborg B; Mäkelä M; Ruma SA; Terävä J; Huhtinen K; Leivo J; Kristjansdottir B; Pettersson K; Sundfeldt K; Gidwani K
Int J Cancer; 2022 Oct; 151(7):1175-1184. PubMed ID: 35531590
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
